脂质体紫杉醇单药或联合卡铂治疗晚期非小细胞肺癌36例

Paclitaxel liposome alone or combined with carboplatin in the treatment of 36 patients with advanced non-small-cell lung cancer

目的:评价以脂质体紫杉醇单药或联合卡铂治疗既往未接受过化疗的晚期非小细胞肺癌的疗效和毒副反应。方法:脂质体紫杉醇135～175mg·m-2,d1,单药,或联合卡铂AUC=5或350mg·m-2,d2,21重复,治疗既往未接受过化疗的晚期非小细胞肺癌36例。结果:可评价疗效33例,部分缓解(PR)8例,有效率(RR)24.2%(8/33),稳定(NC)39.4%(13/33),进展(PD)36.4%(12/33)。不良反应主要为中性粒细胞下降(31/36,86.1%),未发生过敏反应。结论:脂质体紫杉醇为主化疗治疗晚期非小细胞肺癌疗效与普通紫杉醇相当,因在治疗过程中避免了有机溶剂与大剂量激素的使用,减少了与此相关的不良反应。

To evaluate the efficacy and toxicity of paclitaxel liposome alone or combined with carboplatin in the treatment of advanced non-small-cell lung cancer.Methods：Paclitaxel liposome （135-175 mg·m^-2） alone on day 1,or combined with carbopatin （AUC=5 or 350 mg·m^-2） on day 2 of a 21-day cycle was administrated to chemotherapy-nave patients with advanced non-small-cell lung cancer.Results：In 33 evaluable patients,complete response was not observed,partial response rate was 24.2% （8/33）,no change was39.4% （13/33）, and progress disease was36.4% （12/33）. The common adverse effects were neutropenia （86.1% , 31/ 36） , and no hypersensitiveness occurred. Conclusion：Paclitaxel liposome has similar efficacy as paclitaxel in the treatment of advanced non-small-cell lung cancer. In this therapy, the use of polyethoxylated castor oil, ethanol and large dose cremesone can be avoided, so the incidence of the related adverse events can be lowered.